Objectives Patients suffering from age-related macular degeneration (AMD) are rarely actively involved in decision-making, despite facing preference-sensitive treatment decisions. This paper presents a qualitative study to prepare quantitative preference elicitation in AMD patients. The aims of this study were (1) to gain familiarity with and learn about the special requirements of the AMD patient population for quantitative data collection; and (2) to select/refine patient-relevant treatment attributes and levels, and gain insights into preference structures. Methods Semi-structured focus group interviews were performed. An interview guide including preselected categories in the form of seven potentially patient-relevant treatment attributes was followed. To identify the most patientrelevant treatment attributes, a ranking exercise was performed. Deductive content analyses were done by two independent reviewers for each attribute to derive subcategories (potential levels of attributes) and depict preference trends.
Introduction
Neovascular age-related macular degeneration (AMD) is the primary cause of severe visual impairment and blindness in elderly individuals in industrialized countries. While the neovascular form of AMD accounts for only about 10-15 % of all AMD cases, it causes 90 % of disease-related legal blindness. Neovascular AMD means that blood vessels in the eye grow into the retinal and intrachoroidal space, leaking serous fluid to the macula and damaging visual function. The prevalence of AMD at any stage in individuals between 45 and 85 years of age is globally estimated to be about 8.7 %, with higher estimates in older individuals ([80 years of age) than in younger individuals (50-59 years of age) [1] . With the aging of the population, the disease prevalence in Germany is projected to increase considerably in the coming decades. For this chronic and progressive disease, the effectiveness of the currently available treatment options is limited to temporary improvement or stabilization of visual function.
Currently, three medications are available in Germany to treat neovascular AMD: ranibizumab (Lucentis; Novartis), aflibercept (Eylea; Bayer), and bevacizumab (Avastin; Roche). All are administered as intravitreal injections, with differing injection and monitoring schemes. While aflibercept, the most recently approved drug, requires bimonthly monitoring and injections, ranibizumab requires monthly monitoring followed by injections as needed [2, 3] . Bevacizumab, on the other hand, is not approved for treatment in AMD (but is approved as an intravenous cancer therapy), is much less costly than both ranibizumab and aflibercept (about €40 per injection versus about €1000), and is regularly administered and reimbursed by statutory health insurance in Germany, especially in the private practice ambulatory setting in the framework of special contracts with insurance companies. A recent survey among German ophthalmologists revealed that in 2013, about 49 % of prescribed medications for intravitreal injection were non-approved ones [4] . There has been some debate, however, regarding the systemic safety of bevacizumab and its competitors [5] .
In this situation, with ophthalmologists driving the decision on which medication to inject, the pharmaceutical industry being interested in the market shares of its drugs, and insurance companies being dedicated to cost containment, it remains highly questionable whether and to what degree patient preferences play a role in AMD treatment decisions in Germany. Especially since early initiation and adherence to treatment appear to have an impact on treatment effectiveness [6] [7] [8] , patients should be aware and knowledgeable about the characteristics of the available treatments and their preferences should be included in treatment decisions. While previous research has demonstrated the importance of visual function to patients and their increased tolerance of frequent injections [9] , no studies up to now have identified and evaluated patient preferences regarding all potentially patient-relevant treatment attributes and especially the trade-offs that patients are willing to make between them.
Quantitative methods to elicit the preferences of patients, physicians, or other stakeholders are increasingly used to provide input into health care decision-making at different levels [10] [11] [12] [13] [14] [15] [16] . Preference elicitation in an AMD patient population, using two different quantitative elicitation methods-an analytic hierarchy process (AHP) and a discrete choice experiment (DCE)-was therefore planned by the Health Economic Study Group at the Cologne University Hospital (Cologne, Germany) to find out more about patient preferences in this specific indication. Qualitative research was initiated to prepare and guide these quantitative preference elicitation tasks. A recent review of DCEs by Clark et al. [13] revealed that while the number of DCEs and their quality have increased considerably, most studies still lack good qualitative research to adequately prepare experiments. Qualitative methods that have been used in previous studies include (semi-structured) interviews [17] [18] [19] [20] [21] , interviews combined with clinical field observations [18] , and a nominal group technique [22] . The aims of these studies were, for example, to identify and select attributes, to identify perceived mutual dependencies between attributes, and to refine the wording of attributes.
In accordance with the good research practices published by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [10] , a review of the literature [2, 3, 5, [23] [24] [25] [26] and expert interviews (see Appendix 1 in the Electronic Supplementary Material) preceded our qualitative research. These steps revealed that treatment alternatives for AMD can be characterized by a range of potentially patient-relevant attributes: the effect of the injection on visual function; side effects; costs to statutory health insurance; costs to the patient; approval status; injection frequency; and monitoring frequency. Since it was unclear whether these attributes were relevant to patients and which of them were most relevant to patients, and since inclusion of all attributes was assumed to be cognitively too demanding in this elderly, visually impaired population, qualitative research was needed to select and refine the most patient-relevant attributes for inclusion in the stated preference experiments [27] . With our qualitative research, we also intended to obtain a priori information on patient preference trends, which was needed for development of a statistically efficient design for the DCE [11] .
The objectives of the reported focus group interviews were (1) to gain familiarity with and learn about the special requirements of the AMD patient population for quantitative data collection; and (2) to select and refine patient-relevant attributes and levels and to gain insights into patients' preference structures. The Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines were followed in the reporting of the methods and results [28] .
Methods

Study Design, Subjects, and Setting
This study comprised focus group interviews followed by a ranking exercise of identified treatment attributes. Consecutive patients receiving intravitreal injections for AMD at the Cologne University Hospital were contacted by telephone and were subsequently invited to participate in one of the focus groups. The inclusion criteria were a clinical diagnosis of neovascular AMD and visual function of at least 5 % in one eye; receiving intravitreal treatment with an anti-vascular endothelial growth factor (anti-VEGF) drug, such as ranibizumab, aflibercept, or bevacizumab; having sufficient command of the German language for participation in a focus group; and being insured with the statutory health insurance. Patients were excluded if their mental capacity or overall health was (according to their physicians' judgment) insufficient for participation. Each focus group aimed to include a minimum of three patients [29, 30] . We tried to oversample each group to account for patients not being able to participate. The study was reviewed and approved by the ethics committee at the Cologne University Hospital.
Focus Group Interviews
Development of an Interview Guide
The focus groups followed an interview guide based on preselected concepts in the form of seven potentially patient-relevant treatment attributes for the AHP/DCE. The interview guide was developed by two health economists (VV and MD) and reviewed by a clinician (SF) and an economist trained in qualitative research (MH). It structured the interviews and ensured procedural consistency across focus groups. Since an iterative process of interview guide adaptation was followed, data analysis was done immediately following each interview and the guide was refined to be able to address open or unclear issues in the next focus group (see Appendix 2 in the Electronic Supplementary Material).
Proceeding Throughout Focus Groups
The group moderator (MD) opened the focus group interviews with a short introduction and explained the rules for the discussion. The preselected concepts (attributes) were presented to patients in random order and one by one. Patients were first asked in an open question format to communicate their spontaneous thoughts about the attribute. Afterward, participants were given explanations on the attribute and were then asked again to reflect on the role the attribute played in their personal treatment decision. Visual aids (e.g., risk charts of side effects) were used to improve concept understanding and to give additional structure to the interviews (see Appendix 3 in the Electronic Supplementary Material). To conclude the qualitative section, patients were invited to name additional treatment attributes they considered important. Furthermore, patients were asked to rank the treatment attributes individually from most important to least important. For this purpose, patients received all attributes printed on hand cards. Interviews were to be continued until theoretical saturation appeared to be reached (see Appendix 4 in the Electronic Supplementary Material). This was the case if (1) the overall ranking of attributes no longer changed after addition of the ranking scores (RS) of the most recently conducted focus group to the summed RS of all previous focus groups; and (2) the attributes appeared to be clearly understood and adequately framed. In addition to notetaking, all focus groups were audio recorded and fully transcribed verbatim. The researchers conducting the focus groups (MD and VV) are trained health economists with experience in interviewing techniques.
Analyzing Focus Group Results
Deductive qualitative content analyses of the transcripts and notes were performed independently by two researchers. Patients' statements were categorized into codes corresponding to the previously identified treatment attributes [31, 32] . Information on each code (attribute) was clustered into subcategories, which represented potential levels of the attributes. Also, patients' statements indicating the strength of preference were extracted. The analyses were compared and discussed between the researchers to clarify divergent interpretations.
The individual rankings of attributes were summarized in an overall ranking after each focus group. For each patient, the highest ranking attribute of all seven attributes received a score of 7 (most important) and the lowest ranking attribute was assigned a score of 1 (least important). The scores provided by each individual patient were then summed per attribute. This means that the highest RS an attribute could receive equaled the number of attributes that were ranked times the total number of focus group participants.
Results
Study Group Characteristics
Five focus group interviews with a total of 21 patients were performed. Twenty percent of patients who were initially contacted by telephone and invited to the focus groups refused to participate, without providing a reason. The focus group interviews took place prior to patients' injection appointments in a seminar room at the Center for Ophthalmology, between January and March 2014. Our focus groups sequentially included five participants, seven participants, three participants, four participants, and two participants, respectively. Since the larger two focus groups at the beginning were difficult to moderate and did not leave enough room for individuals to share their thoughts, the number of participants was reduced in subsequent interviews. While in the first two focus groups, all invited patients participated, we had four dropouts (e.g., because of illness or transportation problems) in the later focus groups, which led to the small group size of only two participants in the last focus group. The duration of the focus groups was 90-120 min. Patient characteristics are summarized in Table 1 .
Results of Study Objectives
The results of the focus groups are reported in terms of the study objectives. The reported data are based on focus group transcripts, content analyses, and ranking results. Insights and sample patient quotations to illustrate the results are summarized in Tables 2 and 3. Patient quotations are not included in full, since all focus groups were conducted in German.
1. Gain familiarity with and learn about the special requirements of the AMD patient population for quantitative data collection
As illustrated in Table 2 , the focus groups revealed that AMD patients were not familiar with making diseaserelated decisions. Patients emphasized that it was their physicians' task to choose a treatment and make decisions, e.g., about treatment and monitoring frequency. However, when asked-and especially after being informed about the treatment attributes-patients expressed clear opinions about them. Several patient characteristics depicted in Table 1 seemed to influence patients' judgments of attributes. While patients whose treatment had started less than 1 year ago expected an improvement in their visual function, patients who had been treated for several years aimed at stabilization. Of the patients with very limited visual function, some considered improvement a relevant treatment effect and others considered stabilization a relevant treatment effect. Moreover, anxiety regarding injections was lower in patients who had already received several injections.
Patients also tended to prefer treatment characteristics they were familiar with, especially if current treatment was successful. The interviews did not reveal a subgroup of patients who had a completely different preference structure from that of the other patients. Patients had problems in understanding the complex concept of drug approval (Table 2) . A flow chart used to support the verbal explanation enhanced understanding. All supportive materials, such as risk tables of side effects, flow charts of drug approval, and hand cards for the ranking task, were either adapted or newly developed after the first two focus group meetings. Risk tables of side effects were well understood and helped patients to grasp the risks associated with treatments. Nevertheless, it was a challenge for patients to break down this general risk to their own individual risk. For all patients, except for those close to blindness, the focus groups revealed that 100-point sans-serif typefaces for posters and [20 point typefaces for individual reading materials were appropriate.
2. Select and refine patient-relevant attributes and levels, and gain insights into preference structures
The attributes selected for inclusion in the AHP/DCE experiments are highlighted in Fig. 1 , showing the Table 3 . Regarding the visual function attribute, patients spontaneously either expressed the wish for improvement of their visual function or recognized stabilization as the primary (and, in their view, more realistic) treatment outcome. After provision of information on the potential effects that the drugs may have on visual function, patients still described improvement as the preferred (though less realistic) treatment objective. Examples of improved visual abilities were given by patients, such as ''being able to read without a magnifier'', ''driving a car'', or ''recognizing faces'' (see Appendix 4 in the Electronic Supplementary Material). Regarding the side effects attribute, patients reported that they had never experienced any side effects, apart from minor discomfort following surgery, such as light sensitivity or eye irritation. After the figure explaining approval was introduced, the concept of drug approval was better understood: ''I understand this; so if drug A is not approved for disease B, I don't want it for B.'' (Focus Group 3)
''I wouldn't care; it had some approval-I don't care whether it is for disease A or B; it has been tested-that's important.'' (Focus Group 5)
Problems with the side effects attribute (after it was explained to patients) in general and what it means for their personal situation ''It's nice that you write everything in these large letters-I can never read those handouts that the clinic gives to us.'' (Focus Group 5) [Note: the patients are referring to the patient information given to patients at the clinic before the intervention]
Patients were unaware of more severe potential side effects (e.g., endophthalmitis, stroke, or injuries of the eye due to the injection procedure). The open and targeted questioning on the injection and monitoring frequency attributes revealed that patients considered frequencies between 1 and 4 months to be relevant-in particular, monitoring frequencies of five or more months were not appreciated by patients, who expressed a strong need to receive regular reassurance that their disease was ''under control''. Patients did express strong feelings about the approval attribute; again, patients were divided between those who considered approval of ''In my opinion, it is extremely expensive, but if the insurance reimburses it, I assume they accept this price.'' (Focus Group 4) the drug very important and others who stated that approval status did not play a role as long as drug effectiveness was given. Apart from the preselected attributes, patients did not name any other attributes they considered important. During the first focus group, patients experienced difficulties in ranking the seven attributes from most important to least important. Therefore, the complexity of the ranking task was reduced. Patients were asked to sort out the two least important attributes and to order only the remaining five. The overall ranking of the attributes did not change after the third focus group for two consecutive focus groups. As illustrated in Fig. 1 , the five most patient-relevant attributes were the effect on visual function, injection frequency, approval status, side effects, and monitoring frequency. While it appeared throughout the qualitative session that patients neither knew of side effects nor had experienced side effects, the ranking nevertheless revealed that this attribute was among the five most important ones. Although it was difficult for some patients to understand the concept of approval, most patients considered this an important treatment attribute-the third most important in the ranking. The two attributes that were considered least important were the costs to the patient (RS: 70) and the costs to the insurance (RS: 41) (see Fig. 1 ). Although in the ranking task, the difference between costs to the patient and monitoring frequency seemed minor, it became clear from the patients' discussion that, while personal health care costs are relevant to patients in general, they do not play a major role in treatment decisions regarding AMD. The types of costs described by patients were waiting and travel time costs, which do not differ between treatment options. Most patients also agreed that prepayment for drug injections was not considered an issue any more, since the injection fees are now reimbursed by statutory health insurance at relatively short notice (within 2 weeks). Patients also stated that they would consider the cost to statutory health insurance only if it helped reduce their individual insurance payments. Patients perceived several attributes to be interdependent or overlapping. As the majority of patients were treated on a pro re nata (PRN) scheme, they associated the injection frequency with the frequency of monitoring visits. The PRN scheme implies that the decision about further injections is based on monthly monitoring visits with optical coherence tomography (OCT) or a vision test. The description and explanation of other treatment schemes helped patients to understand that injections can also be administered regularly with potentially differing monitoring schemes. Interdependence was also perceived between the costs of the drug and the approval status, as well as between the costs and the effectiveness of a drug. Approved drugs were thought to be more expensive, and more expensive drugs were expected to be more effective. Moreover, patients perceived approved drugs, as well as a greater injection frequency, to be more effective. 
Discussion
This paper presents the process and outcomes of focus group interviews, which were conducted to prepare quantitative patient preference analyses with AHP and DCE in AMD patients. The interviews included a structured discussion among patients and concluded with a ranking of potentially patient-relevant attributes.
Patients considered the effect on visual function, injection frequency, approval status, side effects, and monitoring frequency to be the most relevant attributes. Since no patient subgroup was discerned that had a completely different preference structure from that of the other patients, the inclusion and exclusion criteria used for the quantitative AHP/DCE surveys will be the same as those used in the focus groups. In this specific population, the focus groups suggested that quantitative preference elicitation surveys will have to be interviewer assisted, since, during the focus groups, many patients needed repeated explanations and support. This will facilitate the survey by enabling provision of practical support, e.g., reading the questionnaire out loud to those patients with severe visual impairment, and addressing difficulties in understanding complex attribute concepts. In addition, patients will have to be well informed about the elicitation task and the attributes to be able to make (informed) decisions. Furthermore, the focus groups demonstrate that these patients will have to be constantly encouraged to state their own treatment preferences. Given the observed patients' preferences for treatments they knew of, generic labeling of treatment alternatives will be chosen for the planned DCE survey [33] . Finally, besides sociodemographic information, specific characteristics of these patients (e.g., treatment experience and disease severity) seemed to drive patients' preferences and therefore will have to be elicited in the quantitative surveys. The patients' statements also supported the labeling and framing of attributes for the AHP/ DCE questionnaires. The patient-defined attributes of the level of visual function, injection and monitoring frequency-and the respective ranges and examples provided by the patients, as well as the examples of side effectscan be used as such in quantitative preference elicitation instruments. Special care has to be given to the concise framing of attributes, for which the focus groups revealed conceptual dependencies, such as for the injection attribute with respect to monitoring frequency and for approval/injection frequency with respect to effectiveness. These attributes need to be labeled and framed so that patients can clearly differentiate between them. Furthermore, an efficient DCE design will allow us to take into account the dependency between monthly monitoring and the injections as needed (PRN) treatment scheme by including a fixed combination of these two attribute levels in choice sets. All in all, it is likely that a preference elicitation questionnaire that is based on the patients' own labeling and framing of attributes and levels is a more feasible instrument for patients [27] .
The ranking exercise enabled us to identify a limited number of patient-relevant attributes for inclusion in the quantitative surveys. To minimize the cognitive burden, Hiligsmann et al. [34] also proposed to limit the number of attributes in a ranking task to five. An option to reduce the cognitive burden for each patient in a quantitative elicitation exercise is to include, for example, fewer choice sets in a DCE. Including fewer choice sets for each patient in a DCE, however, might increase the overall minimum sample size required to estimate preferences efficiently [35, 36] . This, on the other hand, makes interviewer-assisted surveys a time-consuming and costly exercise, which also needs to be taken into account in AHP and DCE survey planning. Finally, the focus groups provided clear preference trends that will enter the DCE experimental design as a priori assumptions. Such assumptions are needed when an efficient design is chosen, and they are likely to be more reliable when they are based on preliminary qualitative research in patients.
A previous study by Droege et al. [9] reported high acceptance of monthly injections and monitoring by patients, whose main objective was to achieve at least stabilization of visual function-a trend that was confirmed in this study. However, it seemed that this was explained by the patients' being used to frequent monitoring (especially in the PRN schemes) and being scared of undertreatment. Our study also revealed that if new treatment schemes with less frequent injections and monitoring are introduced, patients might trade these for their current treatment as long as equal effectiveness is maintained. This hypothesis, however, awaits confirmation in the AHP/DCE surveys.
A clear limitation of the study was that the patients were recruited exclusively from the Cologne University Hospital. Patients in other treatment settings (e.g., patients treated at other hospitals or patients seeing ophthalmologists working in the field) and the resulting impact on patient views might not be well captured, and might limit the generalizability of our results. Since the non-approved drug is used only in rare emergency cases at the Cologne University Hospital, the patients' judgments of the drug approval status might have been biased, as the patients might intentionally have chosen to be treated at the Cologne University Hospital because they rejected nonapproved drugs. The observed limited knowledge among patients regarding the AMD drug approval situation, however, did not suggest that this was an important limitation. Moreover, provision of intensive information on attributes that patients seemed not well informed about (e.g., approval and side effects) might have led to overestimation of their perceived importance. Nevertheless, informing patients is essential to enable them to state their preferences. Lastly, privately insured patients and their views were not captured. Given that the majority of patients ([90 %) in Germany are insured with the statutory health insurance, it appeared reasonable to focus on this population.
The smaller group sizes in the last three focus groups could be viewed as another limitation of our study. However, the initial larger focus groups suggested that these elderly and visually impaired patients needed time and room for understanding and communication, which seemed better facilitated in a smaller group. In the larger groups, patients sometimes had difficulties in following each other, understanding what was said, or waiting for their turn to speak, so they started to whisper with each other. As Krueger and Casey [30] pointed out, such observations are a sign that a group might be too large and, to maintain methodologic rigor, the group size should be reduced. The reviewed studies underlined that the size of a focus group should first be determined by the aims of the focus group study [29, 30, 37] . While Barrett and Kirk [37] described the special situation of focus groups in elderly individuals, Stalmeijer et al. [29] stated that ''a minimum number of three or four participants is possible and for some topics may be preferable''. The last focus group, which unintendedly consisted of only two participants, was still considered effective, since the patients discussed the diverse issues in a very lively manner. In addition, since saturation was already obtained, this small number did not represent a problem.
An advantage of doing qualitative research in preparation for quantitative preference elicitation (going beyond answering our study objectives) might also be that interpretation and plausibility checks of the subsequent quantitative results are facilitated, especially if the quantitative preference elicitation itself has no qualitative component such as group discussions or think-aloud tasks. Qualitative research, as described in this paper, may therefore not only improve the feasibility but also increase the face and process validity of quantitative research, hence increasing its external validity. The latter has been recently discussed more intensively by Lancsar and Swait [38] and awaits confirmation in further studies.
Conclusion
This study suggests that qualitative research is a helpful step to prepare the design and administration of quantitative preference elicitation instruments. It especially facilitated familiarization with the target population and its preferences, and supported attribute/level refinement. Furthermore, it might later be of value for interpretation of the results of our quantitative preference elicitation studies.
